X @Bloomberg
Bloomberg·2026-07-30 17:50
Braveheart Bio, a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector. https://t.co/WdKYSOlMGd ...